Urinary and sexual function changes in benign prostatic hyperplasia patients before and after transurethral columnar balloon dilatation of the prostate

Table 1 Comparison of operation time between groups (mean ± SD)

Group	n	Operation time (min)	Intraoperative blood loss (mL)	Bladder irrigation time (h)	Catheter indwelling time (d)	Hospital stay (d)
Study group	70	18.6 ± 3.2	13.2 ± 4.0	6.3 ± 2.0	2.5 ± 0.5	2.9 ± 0.7
Control group	70	80.0 ± 14.8	66.5 ± 18.4	45.1 ± 13.8	5.1 ± 1.2	5.6 ± 1.5
t value		-33.926	-23.683	-23.280	-16.733	-13.647
P value		0.000	0.000	0.000	0.000	0.000

Table 2 Pre- and postoperative changes in urinary symptoms between groups (mean ± SD)

Group	n	Qmax (mL/s)		RUV (mL)		IPSS scores (Score)
		Before therapy	Treatment for 3 mo	Before therapy	Treatment for 3 mo	Before therapy	Treatment for 3 mo
Study group	70	7.69 ± 2.05	20.51 ± 3.04a	98.5 ± 14.3	8.6 ± 2.7a	24.6 ±3 .5	5.1 ± 1.6a
Control group	70	8.20 ± 2.18	19.68 ± 2.88a	101.0 ± 16.5	9.0 ± 3.0a	24.2 ± 3.9	5.3 ± 1.9a
t value		-1.426	1.658	-0.958	-0.829	0.639	-0.674
P value		0.156	0.100	0.340	0.408	0.524	0.502

^aP < 0.05 vs data before treatment in the same group.

Qmax: maximum urine flow rate; RUV: residual urine volume; IPSS: International Prostate Symptom Score.

Table 3 Pre- and postoperative changes in sexual function between groups (mean ± SD, scores)

Group	n	Before therapy	Treatment for 1 mo	Treatment for 3 mo
Study group	70	21.53 ± 2.67	21.30 ± 2.80	22.04 ± 2.67
Control group	70	22.00 ± 2.91	20.04 ± 2.59a	21.81 ± 2.74
t value		-0.996	2.764	0.503
P value		0.321	0.006	0.616

^aP < 0.05 vs data before treatment in the same group.

Table 4 Pre- and postoperative serum prostate-specific antigen levels between groups (mean ± SD, μg/L)

Group	n	Before therapy	Treatment for 1 mo	Treatment for 3 mo
Study group	70	7.52 ± 2.01	4.37 ± 1.49a	3.56 ± 1.33a
Control group	70	7.90 ± 2.46	4.60 ± 1.55a	3.82 ± 1.50a
t value		-1.001	-0.895	-1.085
P value		0.319	0.372	0.280

^aP < 0.05 vs data before treatment in the same group.

Table 5 Pre- and postoperative comparisons of quality of life scores between groups (mean ± SD, scores)

Group	n	Before therapy	Treatment for 1 mo	Treatment for 3 mo
Study group	70	5.83 ± 0.89	2.89 ± 0.64a	2.23 ± 0.60a
Control group	70	5.56 ± 0.90	3.07 ± 0.76a	2.41 ± 0.74a
t value		1.785	-1.516	-1.581
P value		0.077	0.132	0.116

^aP < 0.05 vs data before treatment in the same group.

Table 6 Comparison of surgical complications between groups, n (%)

Group	n	Secondary bleeding	Urinary retention	Bladder neck spasm	Urinary incontinence	Complication rate (%)
Study group	70	1	0	1	1	3 (4.29)
Control group	70	4	1	2	3	9 (12.86)
χ2 value						4.115
P value						0.042